Rapidly bring the
candidates to commercialization
Technical platformsdAb (Nb) is a single-domain antibody containing only VHH domain. Because the VHH crystal has a diameter of 2.5 nm, a length of 4 nm and a molecular weight of only about 15 kDa, which is one tenth of the traditional antibody, it is called Nano body. In 1989, Belgian scientists first discovered Nanobodies in camel blood. With the multiple advantages of small size and easy design, Nanobodies are gradually being regarded as a substitute for traditional monoclonal antibodies for clinical treatment and other applications. They are not only alternatives, but their unique functional characteristics have expanded the application of biotherapy and changed the mode of disease treatment, with huge market potential.
（VHH：variable domain of the heavy chain of heavy-chain antibody）
Technical platform
Biologcial drug inhalation platform For asthma, COPD,COVID-19 and other respiratory deseases;
Drug directly dilivered to the pathological site with high drug usage rate and low systemic toxicity;
Compatable with more portable nebulizer.
Reserve 300 camel immune libraries;
Involving 500 molecular targets;
Specific antibody molecules were obtained efficiently within 3 months.
The first Pichia pastoris based platform for sdAb development in China;
Leading technology in Pichia pastoris fermentation,with the yield more than 20g/L;
500L scale pilot production capacity.
Low molecular weight; Simple structure; There is no mismatch;
High expression level and purification yield;
Stable mass production.
Long-acting strategy based on appropriate HSA targeting sdAb;
Meet different clinical half-life requirements;
Wide application scenarios.
